A Pediatric Primer on Influenza: Insights and Interventions

1.25 CME
1.25 AANP
75 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A Pediatric Primer on Influenza: Insights and Interventions

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education


Support Statement

This activity is supported by an educational grant from Genentech, Inc.


Activity Description

Influenza places a substantial burden on the health of people in the United States each year, with varying impact. The Centers for Disease Control and Prevention estimates that influenza has resulted in between 9 million and 45 million illnesses, between 140,000 and 810,000 hospitalizations, and between 12,000 and 61,000 deaths annually since 2010. Clinical trials and observational data show that early antiviral treatment can shorten the duration of fever and illness symptoms and may reduce the risk of complications from influenza. Pediatric and family practice physicians and other clinicians who evaluate patients must keep apprised of new data regarding the diagnosis and treatment of influenza so they can better identify and help manage influenza in the community, reducing patient morbidity and mortality. Three classes of antiviral drugs are currently available for the prevention and treatment of influenza: neuraminidase inhibitors, adamantanes (although adamantanes are not recommended for use in the United States), and the polymerase inhibitor baloxavir marboxil. This CME/AANP program “Pediatric Primer on Influenza: Insights and Interventions” will utilize the ArcheMedX Intelligent Learning Platform and explore the burden of pediatric influenza. Experts will review best practices for diagnosis as well as selection of the most appropriate treatment in children and adolescents with influenza based on its safety, efficacy, and ability to reduce complications in patients at normal or at high risk.


Target Audience

The intended audience for this activity is pediatricians, family practice physicians, pediatric nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.


Learning Objective(s)

Upon successful completion of this activity, participants should be better able to:

  • Summarize the burden of influenza in the pediatric population, as well as evidence-based recommendations regarding its diagnosis.
  • Evaluate new evidence regarding the use of antivirals for the treatment of pediatric and adolescent influenza. 
  • Utilize antiviral therapy in pediatric and adolescent patients to improve outcomes in those who are at normal or high risk for influenza complications.

Activity Chair

Andrew T. Pavia, MD, FAAP, FIDSA
George and Esther Gross Presidential Professor
Chief, Division of Pediatric Infectious Diseases
University of Utah
Director, Hospital Epidemiology Program
Primary Children's Hospital
Salt Lake City, UT


Faculty

Stan L. Block, MD, FAAP
Professor of Clinical Pediatrics
University of Louisville
University of Kentucky
President, Kentucky Pediatric and Adult Research
Bardstown, KY

Natasha B. Halasa, MD, MPH, FAAP, FIDSA, FPIDS
Associate Professor
Pediatric Infectious Diseases
Vanderbilt University Medical Center
Nashville, TN

Charles P. Vega, MD, FAAFP
Health Sciences Clinical Professor, Department of Family Medicine
Executive Director, Program in Medical Education for the Latino Community
Assistant Dean for Culture and Community Education
University of California, Irvine
Irvine, CA


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

abp mocSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.25 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Participants who successfully complete the program and opt-in by providing their ABP ID and DOB (MM/DD) will earn MOC credits equivalent to the amount of CME credits claimed for the activity.

This activity is approved for 1.25 contact hour(s) of continuing education (which includes 0.75 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20104581. This activity was planned in accordance with AANP Accreditation Standards and Policies.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.

This enduring material is approved for 1 year from the date of original release, November 30, 2020 to November 29, 2021.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate. 


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Activity Chair and Faculty report the following relationship(s)

Stan L. Block, MD, FAAP
Contracted Research: AstraZeneca, Genentech, GlaxoSmithKline, Sanofi, Shionogi

Natasha B. Halasa, MD, MPH, FAAP, FIDSA, FPIDS
Consulting Fee: Karius
Contracted Research: Quidel, Sanofi

Andrew T. Pavia, MD, FAAP, FIDSA
Royalty: Antimicrobial Therapy Inc.
Consulting Fee: Genentech, Merck, Sequirus

Charles P. Vega, MD, FAAFP
No relevant financial relationships to disclose.

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com